BridgeMD
New treatment option for Ischemic Stroke
Official title Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5)
ClinicalTrials.gov ID: NCT07172789
What this study is testing
- What it's testing
- Recent studies suggest that head-down positioning (HDP) intervention may improve outcomes in ischemic stroke. In the era of reperfusion therapy, a key protective strategy is to administer neuroprotective interventions before recanalization to reduce the loss of the ischemic penumbra, thereby salvaging more penumbral tissue after revascularization and ultimately improving clinical outcomes.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years;
- Patients with acute large vessel occlusion scheduled for endovascular thrombectomy within 24 hours of symptom onset;
- Baseline National Institute of Health Stroke Scale (NIHSS) ≥ 6;
- Expected waiting time from randomization to femoral artery puncture is more than 30 minutes;
- ASPECTS/pc-ASPECTS score ≥ 6 on baseline non-contrast CT or DWI;
You likely can't join if
- Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;
- Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more...
- Severe hypertension before randomization (systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg);
- Cardiac insufficiency (NYHA Class ≥II);
- Pregnancy, plan to get pregnant or during lactation;
- Patients at significant risk of aspiration (e.g., obvious nausea and vomiting);
See the full eligibility criteria
- Age ≥ 18 years;
- Patients with acute large vessel occlusion scheduled for endovascular thrombectomy within 24 hours of symptom onset;
- Baseline National Institute of Health Stroke Scale (NIHSS) ≥ 6;
- Expected waiting time from randomization to femoral artery puncture is more than 30 minutes;
- ASPECTS/pc-ASPECTS score ≥ 6 on baseline non-contrast CT or DWI;
- Modified Rankin Scale score before stroke onset ≤ 1;
- Signed informed consent by patient or their legally authorized representative.
- Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;
- Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
- Severe hypertension before randomization (systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg);
- Cardiac insufficiency (NYHA Class ≥II);
- Pregnancy, plan to get pregnant or during lactation;
- Patients at significant risk of aspiration (e.g., obvious nausea and vomiting);
- The estimated life expectancy is less than 6 months due to other serious diseases;
- Other conditions unsuitable for this clinical study assessed by researcher.
The study team makes the final eligibility decision.
Where it's taking place
- Shenyang, None Selected, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenyang, None Selected, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.